GGrantIndex
← Search

EFFECT OF H5G1.1 MONOCLONAL ANTIBODY ON REDUCTION OF PROTEINURIA IN PATIENTS

$0M01FY2000RRNIH

Ohio State University, Columbus OH

Investigators

Linked publications & trials

Abstract

This study is a Phase II randomized, double-blind, placebo-controlled study of the effect of h5G1.1-mAb on the reduction of proteinuria in patients with idiopathic membranous glomerulopathy. The study drug h5G1.1 is administered to research subjects by IV infusion over a period of 30 min. Research subjects are then kept under observation for one hour.

View original record on NIH RePORTER →